This is a phase 1/1b randomized, double blind, placebo-controlled, single dose escalation (SAD) and multiple dose escalation (MAD) study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ZL-1503 in healthy volunteers and participants with moderate to severe atopic dermatitis (AD)
Healthy male and female volunteers, 18-65 years of age
Body mass index (BMI) between ≥ 18.5 and < 32.5 kg/m2
Negative pregnancy tests for women of childbearing potential.
18-65 years of age;
Significant health issues, such as positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), active tuberculosis, immunodeficiencies or autoimmune diseases.
History of major metabolic, liver, kidney, hematologic or other significant disorders.
Abnormal Electrocardiogram (ECG) findings
Clinically relevant abnormal lab results, including low blood counts, or abnormal liver and kidney function.